DDrare: Database of Drug Development for Rare Diseases

500 mg ck-2017357 (DrugBank: -)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
11	重症筋無力症	1

2. 筋萎縮性側索硬化症　［臨床試験数：508，薬物数：530（DrugBank：146），標的遺伝子数：170，標的パスウェイ数：221］

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 508 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01089010 (ClinicalTrials.gov)	March 2010	16/3/2010	A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	A Phase II, Double-Blind, Randomized, Placebo-Controlled, Three-Way Crossover, Pharmacokinetic and Pharmacodynamic Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357	Cytokinetics	NULL	Completed	18 Years	N/A	All	67	Phase 2	United States

11. 重症筋無力症　［臨床試験数：226，薬物数：172（DrugBank：45），標的遺伝子数：43，標的パスウェイ数：118］

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 226 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01268280 (ClinicalTrials.gov)	December 2010	28/12/2010	Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis	A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy	Myasthenia Gravis	Drug: Placebo;Drug: 250 mg CK-2017357;Drug: 500 mg CK-2017357	Cytokinetics	National Institute of Neurological Disorders and Stroke (NINDS)	Terminated	18 Years	80 Years	All	32	Phase 2	United States